217 related articles for article (PubMed ID: 37493631)
1. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.
Stanland LJ; Ang HX; Hoj JP; Chu Y; Tan P; Wood KC; Luftig MA
Mol Cancer Res; 2023 Nov; 21(11):1148-1162. PubMed ID: 37493631
[TBL] [Abstract][Full Text] [Related]
2. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
5. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.
Le X; Antony R; Razavi P; Treacy DJ; Luo F; Ghandi M; Castel P; Scaltriti M; Baselga J; Garraway LA
Cancer Discov; 2016 Oct; 6(10):1134-1147. PubMed ID: 27604488
[TBL] [Abstract][Full Text] [Related]
6. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
7. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
8. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
9. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
10. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
11. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
12. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
14. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
[TBL] [Abstract][Full Text] [Related]
15. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
[TBL] [Abstract][Full Text] [Related]
16. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Fritsch C; Huang A; Chatenay-Rivauday C; Schnell C; Reddy A; Liu M; Kauffmann A; Guthy D; Erdmann D; De Pover A; Furet P; Gao H; Ferretti S; Wang Y; Trappe J; Brachmann SM; Maira SM; Wilson C; Boehm M; Garcia-Echeverria C; Chene P; Wiesmann M; Cozens R; Lehar J; Schlegel R; Caravatti G; Hofmann F; Sellers WR
Mol Cancer Ther; 2014 May; 13(5):1117-29. PubMed ID: 24608574
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
[TBL] [Abstract][Full Text] [Related]
20. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
